G30
Conditions
Interventions
Group 1: Administration of an intravenous bolus of (-)-[18F]NCFHEB (500 MBq) with subsequent neuronal body PET-Scan in volunteers presenting with mild Alzheimers disease
Group 2: Administration of an
Sponsors
Universität Leipzig
Eligibility
Sex/Gender
All
Age
55 Years to No maximum
Inclusion criteria
Inclusion criteria: Healthy volunteers: 1 Males/females aged greater than or equal to 55 years of age, females must be without childbearing potential (confirmed by either: age = 60; or history of hysterectomy; or hormone analysis in serum: Estradiol = 20 pg/mL and follicle stimulating hormone (FSH) = 40 IU/L, or last spontaneous bleeding at least 2 years prior to the study start) 2 Able to understand the information provided on purpose and conduct of the clinical study 3 Have signed the informed consent to participate in the study 4 No history of any psychiatric or neurological diseases. Clinical Dementia Rating (CDR) score of 0 (zero) and psychometric test results lying within an interval of one standard deviation from the mean value (mean value and standard deviations adjusted for age and education), for all subtests of the test battery applied. 5 Brain MRI: medial temporal lobe atrophy (MTA) score = 2 on the Scheltens scale 54 (scale ranging from 0 to 4) 6 Brain MRI: white matter lesion (WML) score = 2 on the Fazekas scale 15 (scale ranging from 0 to 3) 7 Adequate visual and auditory acuity to complete neuropsychological testing, as assessed by the recruiting investigator AD patients 1 Males/females aged greater than or equal to 55 years of age; females must be without childbearing potential (confirmed by either: age = 60; or history of hysterectomy; or hormone analysis in serum: Estradiol = 20 pg/mL and follicle stimulating hormone FSH = 40 IU/L, or last spontaneous bleeding at least 2 years prior to the study start) 2 Capable of understanding the information provided on purpose and conduct of the clinical study and able to give meaningful informed consent by himself / herself 3 Have signed the informed consent to participate in the study 4 Adequate visual and auditory acuity to complete neuropsychological testing, as assessed by the recruiting investigator 5 AD patients, characterized by: a) Progressive cognitive decline with DSM-IV criteria for Dementia b) Probable Alzheimer Disease according to the NINCDS-ARDA criteria c) Severity of dementia: mild, with a score of 1 on the Clinical Dementia Rating (CDR) and 18-26 on the Mini Mental State Examination (MMSE)
Exclusion criteria
Exclusion criteria: Healthy volunteers 1 Clinical significant abnormal physical examination 2 Evidence of any significant psychiatric or neurological illness from history, clinical or para – clinical findings 3 History, physical or imaging findings of any significant neurological illness such as cerebrovascular disease, inflammatory or infectious disease and other neurodegenerative diseases 4 Grossly pathological findings in brain MRI AD patients 1 History, physical or imaging findings of other neurological illness apart from AD such as cerebrovascular disease, inflammatory or infectious disease and other degenerative diseases or other dementia types such as fronto-temporal lobe dementia or Lewy body disease. 2 Use of cholinesterase inhibitors. All subjects 1 Previous significant occupational exposure to ionizing radiation or in whom, within the last 10 years, radioactive substances were applied for the purposes of research. 2 Hematological or biochemical parameters that are outside the normal range and are considered clinically significant by the investigator. 3 History of alcohol or drug abuse/dependence 4 History of major allergic reactions 5 History of epilepsy 6 History of electroconvulsive therapy 7 Any significant disease or unstable medical condition (e.g. unstable angina, myocardial infarction or coronary revascularization in the preceding 12 months, cardiac failure, chronic renal failure, chronic hepatic disease, severe pulmonary disease, blood disorders, poorly controlled diabetes, chronic infection) 8 Criteria which in the opinion of the investigator preclude participation for scientific reasons, for reasons of compliance, or for reasons of the volunteer’s safety 9 Participants in whom magnetic resonance imaging (MRI) is contraindicated. 10 Patient / Volunteer is in custody by order of an authority or a court of law 11 Exclusion periods from other studies or simultaneous participation in other clinical studies 12 Patient / Volunteer has received another investigational drug in the preceding 2 months 13 Previous enrollment in this study 14 Active Smokers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Validation of (-)-[18F]NCFHEB as an in vivo marker of brain a4ß2 nicotinic receptor (nAChR) availability in patients with mild Alzheimer’s disease (AD) compared with controls (healthy volunteers). The hypothesis is that nAChR availability is reduced in AD patients compared to healthy volunteers in brain regions primarely affected in AD such as temporo-parietal and posterior cingulate cortices. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To demonstrate the correlation of reduced a4ß2 nAChRs availability and cognitive declines at one-year follow-up in patients with mild AD 2. Determination of safety and tolerability of (-)-[18F]NCFHEB 3. Determination of the pharmacokinetic parameters and exposure to radiation by (-)-[18F]NCFHEB 4. Development of a kinetic model in order to quantitatively describe regional central a4ß2 nAChR availability in the brain of patients with AD, as well as healthy volunteers | — |
Countries
Germany
Contacts
Public ContactOsama Sabri
Universitätsklinikum Leipzig AöR Dep. of Nuclear Medicine
Outcome results
None listed